| Entry |
|
|---|
| Name |
Tyrosine kinase inhibitor to HER2 overexpression/amplification
|
|---|
| Definition |
(Trastuzumab,Trastuzumab_emtansine,Pertuzumab,Lapatinib,Neratinib,Tucatinib,Margetuximab) -| (ERBB2*,ERBB2*) |
|---|
| Expanded |
(D03257,D09980,D05446,D04024,D10898,D11141,D10446) -| (2064v1,2064v3) |
|---|
| Type |
Drug target
|
|---|
| Gene |
| 2064 | ERBB2; erb-b2 receptor tyrosine kinase 2 |
|
|---|
| Variant |
|
|---|
| Perturbant |
|
|---|
| Reference |
|
|---|
| Authors |
Nahta R, Hung MC, Esteva FJ |
|---|
| Title |
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX |
|---|
| Title |
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. |
|---|
| Journal |
|
|---|
| LinkDB |
|
|---|
